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THE TERM QUESTION: 
COPYRIGHT FOR SOUND RECORDINGS IS A PATENT RIGHT FOR 
INDUSTRIAL CULTURAL PRODUCTION 
 
With the Treasury sponsored Gowers Review on Intellectual Property due to report back, 
and Tony Blair’s leaked support for an extension of the term on sound recordings and 
performers’ rights, I thought I should complete the sketch from my last column on the 
relationship of copyright and contract.  In that piece, I had dismissed the idea that any 
copyright extension would benefit ordinary performing musicians. Simple bargaining 
power ensures that the extended terms will end up in the hands of the same corporate 
interests – the exception being a few best-selling artists who have managed to control 
their contracts.  
 
Unless policy makers are prepared to interfere with the contractual freedom of 
negotiating parties (for example by prescribing royalty terms, or conditions under which 
copyright falls back to the artists), copyright extension is simply a matter of industrial 
policy. Does the music industry produce the right mix of products, and at what price? 
 
It is the same question we ask in patent policy. Exclusive rights are supposed to correct a 
market failure in the supply of desirable goods. As a measure for channelling profits to 
investors, patents are certainly effective. In a case involving GlaxoSmithKline’s best-
selling antibiotic drug Augmentin, a U.S. federal court invalidated, in May 2002, a patent 
on a derivative that was designed to extend Augmentin’s monopoly (due to expire in 
December 2002) until 2018. GSK’s sales of Augmentin had amounted to £912m per year, 
and the judgment wiped 9% from the value of the company. With good reason. Among 
recent precedents stands out the patent on Eli Lilly’s Prozac that expired on 2 August 
2001. Sales immediately dropped by 80% in favour of generic drug alternatives.  
 
There is an extended literature in innovation economics charting market movements after 
the patent term has run out. Similarly, we can expect that the imminent expiry of the term 
for sound recordings for best-selling elements of the music industry’s backcatalogue in 
Europe may have semi-catastrophic effects for the balance sheet of Universal, EMI, 
Sony, Bertelsmann and Warner. This is bad for the Majors, but is it bad for the rest of us? 
Is it the end of music as we know it? 
 
The story of Ibuprofen 
Let’s return to the pharmaceutical analogy with the nice story of “2-(4-
isobutylphenyl)propionic acid”, a phenylalkanoic acid otherwise known as Ibuprofen. 
Synthesised in 1961 at Boots in Nottingham by a team lead by Dr Stewart Adams, 
Ibuprofen’s analgetic properties were discovered by chance in an attempt to produce anti-
inflammatory drugs for the treatment of rheumatoid arthritis. When the patent for the now 
market-leading painkiller ran out in the 1980s, Boots embarked on a major re-branding 
exercise of “targeted pain relief” in orange and shiny metal: Nurofen. Nurofen contains 
the same active ingredient, Ibuprofen, that is now available over the supermarket counter 
at 30 pence. Still, Nurofen continues to trade nearer £3.  
 
As a consumer, this gives me a choice. Do I go for cheap generics, or do I choose the 
Nurofen lifestyle. As a result of competition, we are all better off. Even Boots would not 
argue that society would benefit from reinstating its monopoly rights. You probably sense 
where this is leading. Substitute Boots with EMI, substitute Ibuprofen with the 1958 hit 
Move It, and substitute Dr Adams with Cliff Richard – and you are there. 
 
 
In the locker 
Apart from the undoubted benefits in cheaper and more innovative re-issues of well 
known records that will follow the end of exclusive terms, there is a second major issue 
that needs to be addressed. Record firms sit on large archives of recordings that are no 
longer deemed commercially viable. According to a recent study, only 14% of pre-1965 
recordings are currently available from U.S. right holders (T. Brooks, “How Copyright 
Law Affects Reissues of Historic Recordings: A New Study”, ARSC Journal 36(2), Fall 
2005, available at http://www.clir.org).  In many cases, right holders do no longer even 
physically own the masters, either because they acquired the rights by chance in a 
corporate transaction, or because storage was too costly. 
 
As a society, we cannot allow our recorded musical heritage to be locked up or destroyed. 
Whether compulsory licences, a registration system for re-issues or more radical “use it 
or lose it” measures should be adopted, is a complex question. Here, creative policy 
thoughts are overdue. Most at risk is not main stream culture, but the cultural diversity of 
music hall, ethnic recordings and classical niche repertoire. 
 
 
A final thought: The named inventors of the 1961 Ibuprofen patent did not receive any 
financial reward. More on these themes in my inaugural lecture: “Escape from the 
Garret? Copyright and the tale of the starving artist”. 1 November, 6.30pm, Bournemouth 
University, Talbot Campus. For an invitation, please e-mail Christine Reaks 
(creaks@bournemouth.ac.uk). 
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